INC. (NASDAQ:INCR) Files An 8-K Entry into a Material Definitive Agreement
On October 5, 2020, Red Cat Holdings, Inc., a Nevada corporation (the “Company”), closed a private offering (the “Offering”) to a securities purchase agreement (the “Purchase Agreement”) in which it offered and sold convertible promissory notes (the “Notes”) in the aggregate principal amount of $600,000 and issued five-year warrants (the “Warrants”) to purchase an aggregate of 399,996 shares of common stock, par value $0.001 per share, of the Company.
The Notes accrue interest at the rate of 12% per annum and are payable two years from the date of issuance. The Notes are convertible into shares of the Company’s common stock at a conversion price per share of $1.00 or, upon the consummation by the Company of a Qualified Offering, as such term is defined in the Note, at a price equal to 75% of the price of the securities sold in such Qualified Offering. The holder of the Note also has the right to convert the Note into shares of common stock at any time at a conversion price of $1.00 per share. The Note also provides antidilution protection for the conversion price.
Upon an event of default, as such events are specified in the Note, the conversion price will equal the lower of (i) the thirty day volume weighted average of the closing price of the Company’s common stock if the conversion occurs prior to a Qualified Offering, or (ii) 65% multiplied by the lowest closing price of the common stock during the twenty consecutive trading day period immediately prior to the conversion.
The Company may prepay all or any portion of the Note, without penalty or premium, upon at least ten business days’ prior notice to the noteholder.
Upon issuance by the Company of a security, or amendment to a security, that the noteholder reasonably believes is more favorable, such term, at noteholder’s option, will become a part of the Note, except for certain Exempt Issuances (as defined in the Note).
No conversions under the Note will be effected that will result in the noteholder, together with any affiliate, beneficially owning in excess of 9.99% of the Company’s outstanding common stock immediately after giving effect to such conversion.
The Warrants are exercisable at a price equal to the lower of (i) $1.50 per share or (ii) if a Qualified Offering occurs, at a 25% discount to the price per share of the common stock offered in such Qualified Offering.
The number of shares of common stock for which the Warrant is exercisable is subject to adjustment in the event of a stock split or dividend, and similar event or certain corporate events such reorganizations and mergers.
In the event of a reorganization or reclassification of capital stock, the consolidation or merger, or the sale or other disposition of all or substantially all the property, assets, business, and goodwill of the Company, the warrant holder will be entitled to purchase the kind and amount of shares of capital stock which the Warrant entitled the warrant holder to purchase immediately prior to such event.
The Warrants also include piggyback registration rights.
The foregoing descriptions of the Purchase Agreement, the Notes and the Warrants are qualified in their entirety by reference to the full text of such documents, copies of which are attached as Exhibits 10.14, 10.15 and 10.16, respectively, and are incorporated herein by reference.
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 2.03.
The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02.
The issuances of the Notes and the Warrants described above are exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D as promulgated by the Securities and Exchange Commission under of the Securities Act of 1933, as amended (the “Securities Act”), as transactions by an issuer not involving any public offering.
|10.14||Form of Securities Purchase Agreement|
|10.15||Form of Convertible Note|
|10.16||Form of Common Stock Purchase Warrant|
Red Cat Holdings, Inc. Exhibit
EX-10.14 2 rcat1009form10qexh10_14.htm EXHIBIT 10.14 Exhibit 10.14 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”),…
To view the full exhibit click
About INC. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.